Cargando…

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type

BACKGROUND: To date, no prognostic microRNAs (miRNAs) for isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma multiformes (GBM) have been reported. The aim of the present study was to identify a miRNA signature of prognostic value for IDH1 wild-type GBM patients using miRNA expression dataset f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zheng, Bao, Zhaoshi, Yan, Wei, You, Gan, Wang, Yinyan, Li, Xuejun, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847806/ https://www.ncbi.nlm.nih.gov/pubmed/23988086 http://dx.doi.org/10.1186/1756-9966-32-59

Ejemplares similares

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
por: Shait Mohammed, Mohammed Razeeth, et al.
Publicado: (2022)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
por: Cordner, Ryan, et al.
Publicado: (2023)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
por: Chotirat, Sadudee, et al.
Publicado: (2012)

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
por: Liu, Sidong, et al.
Publicado: (2020)

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
por: Yan, Wei, et al.
Publicado: (2012)

Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant
por: Herold, Ryan A., et al.
Publicado: (2021)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
por: Amary, M. Fernanda, et al.
Publicado: (2014)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS
por: Hu, Lijuan, et al.
Publicado: (2023)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling
por: Wang, Qiangwei, et al.
Publicado: (2018)

Crystal Structure of the Isocitrate Dehydrogenase 2 from Acinetobacter baumannii (AbIDH2) Reveals a Novel Dimeric Structure with Two Monomeric-IDH-Like Subunits
por: Wang, Peng, et al.
Publicado: (2018)

Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
por: KAWAKAMI, Shota, et al.
Publicado: (2017)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
por: Mir Seyed Nazari, P., et al.
Publicado: (2018)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma
por: Costa, Inês N, et al.
Publicado: (2022)

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
por: Willander, Kerstin, et al.
Publicado: (2014)

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate
por: Sesanto, Rae, et al.
Publicado: (2021)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)

Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms
por: Kessler, Jacqueline, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l6e3g0c8kj6vht1je5l4bcviup